Does Henoch-Schönlein purpura have a cure?

There is currently no single "cure" for Henoch-Schönlein purpura (HSP), now clinically referred to as IgA vasculitis, as it is an immune-mediated condition that typically resolves on its own. While the disease is self-limiting in the majority of children, current management focuses on symptom control, preventing complications, and achieving remission in cases where the kidneys or gastrointestinal tract are severely affected.

What is the current treatment approach for IgA vasculitis?

Because Henoch-Schönlein purpura is often self-limiting, the primary goal of medical intervention is supportive care. For patients with mild symptoms, rest, hydration, and non-steroidal anti-inflammatory drugs (NSAIDs) are standard. In more complex cases of Henoch-Schönlein purpura involving severe abdominal pain or renal involvement, clinicians use corticosteroids or immunosuppressive agents to manage inflammation and prevent long-term organ damage.

What research is being done to improve outcomes?

Researchers are currently investigating the underlying immunological triggers of Henoch-Schönlein purpura to better understand why some patients develop chronic kidney disease (IgA nephropathy) while others recover fully. Current research directions include:

• Precision Medicine: Identifying biomarkers that predict which children are at high risk for renal complications.


• Targeted Immunotherapy: Studying monoclonal antibodies to dampen the specific IgA-mediated immune response.


• Clinical Registry Analysis: Leveraging data from communities like the 106 members of DiseaseMaps to track long-term disease progression.

Are there clinical trials for Henoch-Schönlein purpura?

While there is no "cure" in the form of a single vaccine or gene therapy, clinical trials are active. These trials often focus on refining the use of existing immunosuppressants for patients who do not respond to standard therapy. You can monitor the progress of these studies through the NIH ClinicalTrials.gov database by searching for "IgA vasculitis."

What is the expected outlook for patients?

Most children with Henoch-Schönlein purpura experience a complete recovery within four to six weeks. For a smaller percentage—approximately 5% to 10% of cases—the disease may persist or recur, requiring long-term monitoring by a pediatric nephrologist or rheumatologist. As our understanding of the immune system evolves, the outlook for managing severe Henoch-Schönlein purpura continues to improve.

Next steps

• Consult a pediatric rheumatologist or nephrologist to monitor kidney function.


• Join the DiseaseMaps community to connect with other families navigating Henoch-Schönlein purpura.


• Register for updates on the latest clinical trials via the NIH GARD portal.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): IgA vasculitis.


• Orphanet: Henoch-Schönlein purpura (ORPHA:3303).


• OMIM (Online Mendelian Inheritance in Man): IgA vasculitis.


• The Vasculitis Foundation: Information on IgA Vasculitis/HSP.